NASDAQ OMX

Oxford Immunotec Reports First Quarter 2016 Financial Results

Del
  • First quarter revenue of $17.1 million, increased 24% compared to prior year period
  • Over 7 million cumulative tests sold through the end of the quarter

OXFORD, United Kingdom and MARLBOROUGH, Mass., May 03, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced first quarter 2016 financial results.

“We are very happy with our first quarter financial and operating results,” said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. "Our sales performance was in line with our expectations, with solid growth coming from our United States and Asia geographies.”

By revenue type, total revenues were, in millions:

      
    Three Months Ended March 31,
      2016       2015     Percent 
Change
             
Product   $ 8.1     $ 7.1       14 %
Service     9.0       6.7       34 %
Total Revenue   $ 17.1     $ 13.8       24 %
                           

By geography, total revenues were, in millions:

     
    Three Months Ended March 31,
            Percent Change
      2016       2015     As
Reported
  Constant
Currency 
(1)
                 
United States   $ 8.7     $ 6.4       37 %     37 %
Europe & ROW     1.6       1.7       -8 %     -3 %
Asia     6.8       5.7       19 %     15 %
Total Revenue   $ 17.1     $ 13.8       24 %     23 %
                                 

(1) We evaluate our revenue on both an as reported and a constant currency basis. The constant currency presentation, which is a non-GAAP measure, excludes the impact of fluctuations in foreign currency exchange rates.

First Quarter 2016 Financial Results

Revenue for the first quarter of 2016 was $17.1 million, representing 24% growth over the first quarter 2015 revenue of $13.8 million. On a constant currency basis, revenue growth was 23% versus the prior year period.

2016 first quarter product revenue was $8.1 million representing a 14% increase from product revenue of $7.1 million in the first quarter of 2015. The increase in product revenue was primarily attributable to growth in Asia. Service revenue for the first quarter of 2016 was $9.0 million, up 34% from the 2015 first quarter revenue of $6.7 million. The increase in service revenue was primarily driven by growth in the United States.

United States revenue was $8.7 million in the first quarter of 2016 representing 37% growth over the same period's revenue of $6.4 million in the prior year. Growth was driven primarily by volume increases in the institutional and patient testing segments.

Europe & ROW revenue was $1.6 million in the first quarter of 2016 representing an 8% decrease compared to first quarter of 2015. On a constant currency basis, Europe & ROW decreased 3% versus the first quarter of 2015.

Asia revenue was $6.8 million in the first quarter of 2016 representing 19% growth over 2015 first quarter revenue of $5.7 million. On a constant currency basis, Asia grew 15% versus the first quarter of 2015. The increase was driven by continued strong growth in Japan. China growth was more muted due to the timing of orders in 2015.

Gross profit for the first quarter of 2016 was $8.9 million, an increase of $1.8 million over gross profit of $7.1 million in the same period of 2015. Gross margin was 52.3%, an increase of 50 basis points from the gross margin of 51.8% in the first quarter of 2015. The increase in gross margin was primarily due to mix and lower kit costs associated with increased volume, offset by the costs associated with ongoing process refinement in our Memphis laboratory as well as the ongoing investment into broadening our service capabilities.

Operating expenses were $16.1 million in the first quarter of 2016, an increase of $2.4 million compared to $13.7 million in the same period last year. The increase in operating expenses was primarily due to headcount increases related to both sales and marketing and general and administrative functions, as well as increased costs from clinical studies performed during the quarter.

EBITDA for the fourth quarter was $(6.4) million compared to $(5.8) million in the first quarter of 2015. Adjusted EBITDA was $(5.8) million for the first quarter compared to $(5.0) million in the same period in 2015. Both EBITDA and Adjusted EBITDA are non-GAAP measures.

Net loss for the first quarter of 2016 was $7.0 million, or $0.32 per share, compared to $6.3 million, or $0.31 per share, in the first quarter of 2015. Net loss per share was based on 22,284,392 and 20,331,411 weighted average ordinary shares outstanding for the first quarters of 2016 and 2015, respectively. 

Cash and cash equivalents were $68.7 million as of March 31, 2016 compared to $83.7 million as of December 31, 2015. Cash usage during the quarter was in line with expectations.  The first quarter typically has the highest cash usage as a result of the pre-payment of royalties and payment of year-end bonuses.

Business Outlook

We expect to report full year 2016 revenue of between $74 and $77 million, representing 18%-23% year-over-year growth.

We expect to report revenue of between $17.4 and $18.2 million for the second quarter of 2016.

Conference Call

Oxford Immunotec will host a conference call on Tuesday, May 3, 2016 at 8:00 a.m. Eastern Time to discuss its first quarter 2016 financial results. The call will be concurrently webcast. To listen to the conference call on your telephone please dial (855) 363-5047 for United States callers and +1 (484) 365-2897 for international callers and reference confirmation code 89843505 approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com. The replay will be available on the Company's website for approximately 60 days.

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions.  The Company's first product is the T-SPOT®.TB test, which is used to test for tuberculosis infection.  The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China.  The T-SPOT.CMV test and the T-SPOT.PRT test are the Company's second and third products and part of a series of products intended for the transplantation market.  In addition to these three products, the Company has an additional six active development programs, each of which leverages our T cell, B cell and innate immune measuring technology.  The Company is headquartered near Oxford, U.K. and in Marlborough, Mass.  Additional information can be found atwww.oxfordimmunotec.com.

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.

Forward-Looking Statements

This release contains forward-looking statements, including statements regarding future revenues, expenses and the prospects for sales of our products. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, decisions by regulatory authorities, hospitals and other health care institutions, laboratories, physicians, patients and third party payers, as well as our ability to expeditiously and successfully expand our sales and distribution networks and the other factors described under the "Risk Factors" section in our filings with the Securities and Exchange Commission. When evaluating Oxford Immunotec's business and securities, investors should give careful consideration to these risks and uncertainties.

Forward-looking statements are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. You should not place undue reliance on forward-looking statements, which speak only as of the date of this presentation. We do not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.

CONTACTS:

For Media Inquiries: 
Caroline Crawley
Oxford Immunotec
Tel: +44 1235 442796

ccrawley@oxfordimmunotec.com

For Investor Inquiries:
Rick Altieri
Chief Financial Officer
Oxford Immunotec
Tel: +1 (508) 573-9953

raltieri@oxfordimmunotec.com

Mark Klausner
Westwicke Partners
Tel: +1 (443) 213-0501

oxfordimmunotec@westwicke.com

 
Oxford Immunotec Global PLC
Condensed consolidated statements of operations
(unaudited)
 
    Three months ended March 31,
(in thousands, except share and per share data)     2016       2015  
Revenue        
Product   $   8,138      $   7,122   
Service       8,972          6,679   
Total revenue       17,110          13,801   
Cost of revenue        
Product       3,293          3,070   
Service       4,872          3,585   
Total cost of revenue       8,165          6,655   
Gross profit       8,945          7,146   
Operating expenses:        
Research and development       3,076          2,359   
Sales and marketing       8,480          7,441   
General and administrative       4,583          3,867   
Total operating expenses       16,139          13,667   
Loss from operations       (7,194 )       (6,521 )
Other income (expense):        
Interest expense, net       (17 )       (15 )
Foreign exchange gains       363          165   
Other (expense) income       (166 )       107   
Loss before income taxes       (7,014 )       (6,264 )
Income tax expense       35          47   
Net loss   $   (7,049 )   $   (6,311 )
         
Net loss per share attributable to ordinary shareholders—basic and diluted   $   (0.32 )   $   (0.31 )
         
Weighted-average shares used to compute net loss attributable to ordinary shareholders—basic and diluted       22,284,392          20,331,411   
         
 
Reconciliation of net loss to Adjusted EBITDA (1)
(unaudited)
 
    Three months ended March 31,
(in thousands)     2016       2015  
Net loss   $   (7,049 )   $   (6,311 )
Income tax expense       35          47   
Interest expense, net       17          15   
Depreciation and amortization       581          453   
EBITDA     (6,416 )       (5,796 )
         
Reconciling items:        
Share-based compensation expense       1,104          875   
Unrealized exchange gains       (522  )       (156 )
Change in fair value of contingent purchase price consideration       55          47   
Adjusted EBITDA   $   (5,779 )   $   (5,030 )
         

(1) Adjusted EBITDA is a non-GAAP measure that we calculate as net loss, adjusted for the impact of earnings or charges resulting from matters that we consider not to be indicative of our ongoing operations. We believe that Adjusted EBITDA provides useful information to investors in understanding and evaluating our operating results in the same manner as our management and Board of Directors. Our presentation of Adjusted EBITDA is not made in accordance with U.S. GAAP, and our computation of Adjusted EBITDA may vary from others in the industry. Our use of Adjusted EBITDA has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results as reported under U.S. GAAP.

The above table presents a reconciliation of net loss, the most comparable U.S. GAAP measure, to Adjusted EBITDA for each of the periods indicated.

 
Oxford Immunotec Global PLC
Condensed consolidated balance sheets
(unaudited)
 
    March 31,   December 31,
(in thousands, except share and per share data)     2016       2015  
Assets        
Current assets:        
Cash and cash equivalents   $ 68,731     $ 83,715   
Accounts receivable, net     8,427       7,058   
Inventory     8,479       7,099   
Prepaid expenses and other     3,439       3,592   
       
Total current assets     89,076       101,464   
Restricted cash, non-current     80       80   
Property and equipment, net     6,526       6,284   
In-process research and development     1,855       1,782   
Goodwill     47       45   
Other intangible assets, net     163       179   
Other assets     20       18   
         
Total assets   $ 97,767     $ 109,852   
         
Liabilities and shareholders’ equity        
Current liabilities:        
Accounts payable   $ 2,595     $ 3,799   
Accrued liabilities     6,785       9,949   
Deferred income     106       1,654   
Current portion of loans payable     80       79   
         
Total current liabilities     9,566       15,481   
Long-term portion of loans payable     366       386   
Contingent purchase price consideration     1,403       1,293   
         
Total liabilities     11,335       17,160   
         
Shareholders’ equity:        
Ordinary shares, £0.006705 nominal value; 36,183,293 shares authorized at March 31, 2016 and December 31, 2015, and 22,566,475 and 22,549,488 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively     243       243   
Additional paid-in capital     245,148       244,033   
Accumulated deficit     (153,356 )     (146,307 )
Accumulated other comprehensive loss     (5,603 )     (5,277 )
         
Total shareholders’ equity     86,432       92,692   
         
Total liabilities and shareholders’ equity   $ 97,767     $ 109,852   
         

Om NASDAQ OMX

NASDAQ OMX
NASDAQ OMX
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra NASDAQ OMX

Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra NASDAQ OMX

Aviva Leverages Appian to Deliver on Digital Transformation Initiatives24.10.2017 13:00Pressemelding

With the Appian Platform, Aviva is Anchoring Around the Customer, Removing Complexities and Streamlining Operations RESTON, Va., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Appian (NASDAQ:APPN) today announced Aviva, the UK's largest insurer and one of Europe's leading providers of life and general insurance, has deployed Appian's low-code platform to execute on its global digital transformation journey. Putting the customer first helps with Aviva's aim to deliver an unparalleled customer experience. Embedded in three key business units, Appian is helping to transform the way Aviva manages 'Life and Pensions,' 'General Insurance,' and 'Accident and Health.' Aviva has created more than 10 enterprise-grade applications on the Appian platform with a focus on automating processes, streamlining back office operations and creating a single customer view - decreasing operating costs as a result. The company has also digitized pension operations, modernized new produc

eGain Virtual Assistant(TM) named KMWorld Trend-Setting Product for second year in a row24.10.2017 12:30Pressemelding

Solution recognized for delivering a connected, conversational experience SUNNYVALE, Calif., Oct. 24, 2017 (GLOBE NEWSWIRE) -- eGain (NASDAQ:EGAN), the leading provider of customer engagement solutions, today announced that its AI-powered solution, eGain Virtual Assistant(TM), has been named in KMWorld Magazine's list of Trend-Setting Products of 2017. Sandra Haimila, Editor at KMWorld, said, "Each year KMWorld looks for software products that break new territory in helping organizations leverage knowledge to achieve their business goals. These products are designed, developed and perfectly timed to fill a niche in the marketplace often before users are even aware that they need such tools." eGain Virtual Assistant is a trend-setter especially because of its integration with human-assisted touchpoints, according to Haimila. Solution highlights: Assists with broad range of inquiries - informational, transactional, and advisory

Dahua Technology H.265 Wi-Fi Cameras A26/C26 Serves Consumer Market24.10.2017 12:26Pressemelding

HANGZHOU, China, Oct. 24, 2017 (GLOBE NEWSWIRE) -- To better serve consumer users, Dahua Technology, a leading solution provider in the global video surveillance industry, released its H.265 Consumer Series products earlier this year. It is now available to most of its markets globally. Below are the details about 2 selected cameras - the indoor cube model C26 and the Pan& Tilt model A26. In an era when people are less and less at home, they are in urgent need of a way to stay connected to it. A26/C26 came along to solve the problem. C26 supports intelligent Human Detection and instant alert, keeping consumers aware of what is going on at home any time they want. Smart Tracking of A26/A46 automatically tracks and keeps tracking any moving object around the camera. Feature Highlights: Fluent High-resolution Video based upon H.265 With 2MP image sensor, A26/C26 delivers crystal clear image. The late

Corporate R&D spending hits record highs for the Top 1000, despite concerns of economic protectionism24.10.2017 08:00Pressemelding

Annual worldwide R&D spending breaks through $700bn for the top 1000 corporate R&D spenders for first time 25% of executives surveyed reported having already experienced some pressure to change how or where they conduct innovation Amazon is the world's largest corporate spender on R&D at over $16bn Alphabet surpasses Apple, according to a global survey of R&D executives, as the Most Innovative Company and for the first time a Chinese company, Alibaba joins the Top 10 Most Innovative Companies list NEW YORK, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Annual worldwide corporate R&D spending broke through $700bn in annual investment, according to an annual analysis of R&D spending across 1000 global public companies by P

TEAM Industries Announces New Innovative Transmission Incorporating Fallbrook's NuVinci® CVP Technology24.10.2017 02:25Pressemelding

Design is ready for vehicle implementation in powered recreational and utility vehicles CEDAR PARK, TEXAS and BAGLEY, MINNESOTA, Oct. 23, 2017 (GLOBE NEWSWIRE) -- TEAM Industries (TEAM) and Fallbrook Technologies Inc. (Fallbrook) announced today that TEAM has a production-ready innovative new transmission design for all-terrain vehicles (ATV) and utility task vehicles (UTV) available to OEMs for vehicle implementation. The transmission incorporates Fallbrook's NuVinci® continuously variable planetary (CVP) technology. NuVinci is a platform technology for a new class of continuously variable transmissions (CVT). It utilizes spheres instead of gears or belts, and can be deployed in a wide variety of applications to improve performance and/or system efficiency. TEAM has an exclusive licensing agreement with Fallbrook for the use of NuVinci CVP technology in North America and Europe in electric and gasoline light vehicle applications. TEAM is also workin

Telix Pharmaceuticals and ANMI Partner for Prostate Cancer Imaging24.10.2017 01:00Pressemelding

MELBOURNE, Australia and LIÈGE, Belgium, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (Telix, Company), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly-targeted radiation (MTR), is pleased to announce that it has entered into a development and commercialization partnership with Advanced Nuclear Medicine Ingredients SA (ANMI). Under the terms of the agreement, Telix and ANMI will partner to commercialise ANMI's 68Ga-HBED-CC-PSMA (68Ga-PSMA-11) kit (Kit), a proven technology used to accurately image and stage metastatic prostate cancer, in the US market. Telix will also offer the Kit on a worldwide basis as a companion diagnostic imaging agent to the Company's prostate cancer therapeutic (TLX-591)1. The agreement includes filing a Drug Master File (DMF) for the Kit, and completion of the necessary clinical trials to obtain marketing authorisatio

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom